Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma

$Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma$

Journal article

Peer reviewed

Clinical lymphoma, myeloma and leukemia, Vol.19(10), pp.e559-e563

10/2019

PMID: 31377210

Abstract

Allogeneic transplant

Nivolumab

PD-1

PD-1 inhibitor

PD-L1

Plasmablastic lymphoma

1 Record Views

Title: Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma
Creators - without role: Moussab Damlaj - King Abdulaziz Medical City
Mohammed Alzayed - King Saud bin Abdulaziz University for Health Sciences
Bader Alahmari - King Abdulaziz Medical City
Ayman Alhejazi - King Abdulaziz Medical City
Ahmed Alaskar - King Saud bin Abdulaziz University for Health Sciences
Mohsen Alzahrani - King Saud bin Abdulaziz University for Health Sciences
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.19(10), pp.e559-e563
Publisher: Elsevier Inc
Identifiers: 9920958608331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article